| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Munir Pirmohamed | Q20127995 |
| P2093 | author name string | Farhad Kamali | |
| P2860 | cites work | Cytochrome P4502C9: an enzyme of major importance in human drug metabolism | Q24683497 |
| CYP2C9 allelic variants: ethnic distribution and functional significance | Q28212029 | ||
| Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 | Q28242581 | ||
| Identification of the gene for vitamin K epoxide reductase | Q28242592 | ||
| Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. | Q34283903 | ||
| The influence of age, liver size and enantiomer concentrations on warfarin requirements | Q34347371 | ||
| Common VKORC1 and GGCX polymorphisms associated with warfarin dose | Q34417386 | ||
| A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. | Q34418092 | ||
| Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose | Q34423204 | ||
| Flexible induction dose regimen for warfarin and prediction of maintenance dose | Q34548246 | ||
| The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism | Q34735686 | ||
| Risk factors for bleeding in patients taking coumarins. | Q35193074 | ||
| Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population | Q35583944 | ||
| Frequency of cytochrome P450 2C9 mutant alleles in a Korean population | Q36055401 | ||
| Factors affecting the maintenance dose of warfarin | Q37110242 | ||
| Effect of age upon the induction and maintenance of anticoagulation with warfarin. | Q38639783 | ||
| Ethnic differences in CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) genotypes in Japanese and Israeli populations | Q39194380 | ||
| Aging and the anticoagulant response to warfarin therapy | Q43672961 | ||
| Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans | Q43675710 | ||
| Patient-specific factors predictive of warfarin dosage requirements | Q44146616 | ||
| Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients | Q44351201 | ||
| Racial background is a determinant factor in the maintenance dosage of warfarin. | Q44534843 | ||
| Warfarin dose adjustments based on CYP2C9 genetic polymorphisms | Q44546032 | ||
| Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial | Q44672192 | ||
| Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity | Q44680862 | ||
| Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin | Q44724648 | ||
| Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin | Q44787224 | ||
| A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. | Q45052744 | ||
| Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose | Q45062168 | ||
| The influence of ethnicity on warfarin dosage requirement | Q46458606 | ||
| The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen | Q46537717 | ||
| Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians | Q46650072 | ||
| Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations | Q46696260 | ||
| Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population | Q47957665 | ||
| Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes | Q47961549 | ||
| Factors determining the maintenance dose of warfarin in Chinese patients. | Q51020114 | ||
| Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. | Q52106400 | ||
| Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. | Q52550127 | ||
| Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. | Q53335803 | ||
| The influence of (R)- and (S)-warfarin, vitamin K and vitamin K epoxide upon warfarin anticoagulation. | Q54041860 | ||
| VKORCI haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation | Q58273734 | ||
| Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications | Q63241969 | ||
| Prospective evaluation of a flexible protocol for starting treatment with warfarin and predicting its maintenance dose | Q69717081 | ||
| Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators | Q71016449 | ||
| The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics | Q71064706 | ||
| Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9 | Q71996232 | ||
| Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials | Q72030226 | ||
| Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese | Q72293605 | ||
| Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group | Q72669442 | ||
| Prospective evaluation of a modified Fennerty regimen for anticoagulating elderly people | Q73214217 | ||
| Initiating and Maintaining Patients on Warfarin Anticoagulation: The Importance of Monitoring | Q73468973 | ||
| Anticoagulation of older patients: a need to modify current practice | Q73470048 | ||
| Vitamin K intake and sensitivity to warfarin in patients consuming regular diets | Q74671072 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | anticoagulation | Q63279445 |
| P304 | page(s) | 746-751 | |
| P577 | publication date | 2006-06-01 | |
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| P1476 | title | The future prospects of pharmacogenetics in oral anticoagulation therapy | |
| P478 | volume | 61 |
| Q36729204 | A pilot study of the association of pharmacokinetic and pharmacodynamic parameters of warfarin with the dose in patients on long-term anticoagulation |
| Q36855608 | Cytochrome P450 (CYP2C9*2,*3) & vitamin-K epoxide reductase complex (VKORC1 -1639G |
| Q42707554 | Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients |
| Q36921008 | Exposure to non-therapeutic INR in a high risk cardiovascular patient: potential hazard reduction with genotype-guided warfarin (Coumadin) dosing |
| Q33990428 | Implementing genotype-guided antithrombotic therapy |
| Q36965475 | Integrating genomic based information into clinical warfarin (Coumadin) management: an illustrative case report. |
| Q36898747 | Predict, prevent and personalize: Genomic and proteomic approaches to cardiovascular medicine |
| Q36044022 | Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes |
| Q33990441 | Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics. |
| Q34494596 | Prevalence of genetic variants associated with cardiovascular disease risk and drug response in the Southern Indian population of Kerala. |
| Q50348713 | Prospective pilot trial of PerMIT versus standard anticoagulation service management of patients initiating oral anticoagulation. |
| Q37517041 | Should all anticoagulated patients with head injury receive a CT scan? Decision-analysis modelling of an observational cohort. |
| Q37160370 | Should we test for CYP2C9 before initiating anticoagulant therapy in patients with atrial fibrillation? |
| Q38120951 | The changing face of oral anticoagulants |
| Q37082703 | The new biology: a bridge to clinical cardiology |
| Q41968877 | VKORC1 pharmacogenomics summary |
| Q83527915 | Warfarin-induced skin necrosis |
| Q24678632 | Warfarin: almost 60 years old and still causing problems |
Search more.